The newest ACA final rule is here with more guidance for agents selling in the individual marketplace. CMS aims to reduce premiums for clients with the policy outlined in the Notice of Benefit and Payment Parameters for 2027. ⟶
Review this list of CMS-announced Maximum Fair Prices for drugs in the Medicare Drug Price Negotiation Program. Price reductions for the Medicare-negotiated drugs may help your clients with their prescription drug costs!
After years of remaining as temporary guidance, CMS is looking to expand the Medicare Drug Price Negotiation program affecting Part B and Part D into a permanent structure by 2029.
Ritter Insurance Marketing hosts annual Summits where insurance agents gather to get an exclusive first look at the next year's Medicare Advantage and Part D plan offerings.
The NABIP Medicare certification training for 2027 will be available June 22! Learn the NABIP MA certification release date and if this certification is right for you.
Do you know what your Medicare clients likely spend the most money on out of pocket? Do your clients know what out-of-pocket costs they can expect with Medicare? Here are the most common Medicare out-of-pocket expenses.
If you're an insurance agent who sells Medicare plans, it's time to consider how you need to adjust to better serve your clients and their changing needs.
The Content Library offers you stylish and compliant materials to bolster your content marketing and client retention. Whether you're filling out a newsletter or helping clients understand a complex insurance topic, The Content Library is here for you.
CMS' 2027 Medicare Advantage and Part D Advance Notice is here! Here's how we interpret it and what disruption may lie ahead for insurance agents selling Medicare plans this AEP.
We've got the Centers for Medicare & Medicaid Services' most recent list of Medicare Part B drugs your clients may pay reduced coinsurance for from January through March 2026, thanks to the Medicare Prescription Drug Inflation Rebate Program.
Beneficiaries will soon have access to lower-priced GLP-1 medications through a new pricing model, BALANCE. The previously announced GENEROUS model acts as a bridge for this program.